HUE068643T2 - Hajhullási rendellenességek kezelése deuterált JAK-inhibitorokkal - Google Patents

Hajhullási rendellenességek kezelése deuterált JAK-inhibitorokkal

Info

Publication number
HUE068643T2
HUE068643T2 HUE17793380A HUE17793380A HUE068643T2 HU E068643 T2 HUE068643 T2 HU E068643T2 HU E17793380 A HUE17793380 A HU E17793380A HU E17793380 A HUE17793380 A HU E17793380A HU E068643 T2 HUE068643 T2 HU E068643T2
Authority
HU
Hungary
Prior art keywords
deuterated
treatment
hair loss
jak inhibitors
loss disorders
Prior art date
Application number
HUE17793380A
Other languages
English (en)
Hungarian (hu)
Inventor
Amanda Wagner
James Cassella
Philip Graham
Virginia Braman
Vinita Uttamsingh
Hehn Jana Von
Colleen Hamilton
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE068643(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of HUE068643T2 publication Critical patent/HUE068643T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17793380A 2016-05-04 2017-05-04 Hajhullási rendellenességek kezelése deuterált JAK-inhibitorokkal HUE068643T2 (hu)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01

Publications (1)

Publication Number Publication Date
HUE068643T2 true HUE068643T2 (hu) 2025-01-28

Family

ID=60203616

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17793380A HUE068643T2 (hu) 2016-05-04 2017-05-04 Hajhullási rendellenességek kezelése deuterált JAK-inhibitorokkal

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP4424367A3 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR20250070139A (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241345T1 (hr) 2016-05-04 2024-12-20 Sun Pharmaceutical Industries, Inc. Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak
CN113906032A (zh) * 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
EP4236956A1 (en) * 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
US20250275977A1 (en) 2022-05-04 2025-09-04 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
US20260021047A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TWI665200B (zh) 2009-01-15 2019-07-11 英塞特公司 製造jak抑制劑之方法及相關中間化合物
PL2635299T3 (pl) * 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
ES2867048T3 (es) 2012-06-15 2021-10-20 Concert Pharmaceuticals Inc Derivados deuterados de ruxolitinib
BR112015001839A2 (pt) * 2012-07-30 2017-07-04 Concert Pharmaceuticals Inc ibrutinibe deuterado
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
HRP20241345T1 (hr) 2016-05-04 2024-12-20 Sun Pharmaceutical Industries, Inc. Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak

Also Published As

Publication number Publication date
HRP20241345T1 (hr) 2024-12-20
EP3452039A4 (en) 2019-12-25
DK3452039T3 (da) 2024-10-07
CN109069493A (zh) 2018-12-21
US12076323B2 (en) 2024-09-03
RS66006B1 (sr) 2024-10-31
SI3452039T1 (sl) 2024-12-31
KR102810262B1 (ko) 2025-05-19
ES2988629T3 (es) 2024-11-21
JP2025026895A (ja) 2025-02-26
EP3452039A1 (en) 2019-03-13
MX2023002323A (es) 2023-03-22
PT3452039T (pt) 2024-10-07
US20200222408A1 (en) 2020-07-16
MX2023002325A (es) 2023-03-22
MX2023002321A (es) 2023-03-22
AU2017261286A1 (en) 2018-11-22
AU2025213576A1 (en) 2025-08-21
PL3452039T3 (pl) 2024-11-18
KR20250070139A (ko) 2025-05-20
JP2019516684A (ja) 2019-06-20
BR112018072339A2 (pt) 2019-02-19
JP7586868B2 (ja) 2024-11-19
KR20190003711A (ko) 2019-01-09
AU2017261286B2 (en) 2023-03-23
US20190160068A1 (en) 2019-05-30
WO2017192905A1 (en) 2017-11-09
MX2018013347A (es) 2019-09-02
CA3022519A1 (en) 2017-11-09
MX2023002324A (es) 2023-03-22
SMT202400389T1 (it) 2024-11-15
EP4424367A2 (en) 2024-09-04
EP3452039B1 (en) 2024-07-03
FI3452039T3 (fi) 2024-10-02
AU2023201112A1 (en) 2023-03-30
US10561659B2 (en) 2020-02-18
JP7145080B2 (ja) 2022-09-30
AU2023201112B2 (en) 2025-05-08
EP4424367A3 (en) 2024-11-13
JP2022171838A (ja) 2022-11-11
MX2021014175A (es) 2022-01-04
US20240423986A1 (en) 2024-12-26
KR20230086814A (ko) 2023-06-15
MX388054B (es) 2025-03-19
LT3452039T (lt) 2024-10-25

Similar Documents

Publication Publication Date Title
SI3452039T1 (sl) Zdravljenje motnje izpadanja las z devteriranimi inhibitorji jak
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA202006746B (en) Methods of treatment
IL267229A (en) Methods of treating ocular disorders
IL270781A (en) Treatment of depressive disorders
SG11201607881SA (en) Methods of treating nail and scalp psoriasis
IL270900A (en) Treatment of cutaneous disorders
HUE062857T2 (hu) Készítmény hajnövekedési rendellenességek megelõzésére és kezelésére
HUE064403T2 (hu) A H3-ligandumok új terápiás alkalmazása
ZA201705847B (en) Treatment of pain
IL256249A (en) The vehicle for treating hair loss and increasing its growth
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL265259A (en) Treatment of multiple sclerosis with chs-131
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ZA202002910B (en) Treatment of skin disorders
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL251862A0 (en) Combined treatment to delay hair loss
GB201604359D0 (en) Treatment of tissue disorders
SG11202007642RA (en) Treatment of disorders with tasimelteon
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201700308D0 (en) Hair treatment methods
GB201602641D0 (en) Treatment of fibrotic disorders
GB201602640D0 (en) Treatment of fibrotic disorders
HK40006632A (en) Treatment of pain
PH32016001115S1 (en) Scalp massager